Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Scott Zellner, senior director at DePuy Synthes, and orthopedic surgeon Joel Matta, who has been collaborating with DePuy since 2004, have long advocated for the anterior approach to total hip replacement, touting the many benefits of the minimally invasive surgery. Medtech Insight sat down with Zellner and Matta at this year's American Association of Orthopedic Surgeons' (AAOS) conference in Las Vegas to discuss the company's latest technologies designed for the anterior approach to total hip replacement, what's next, and to hear Matta's view on the widely discussed role of robotic-assisted surgeries.
About eight months into his role as CEO of Smith & Nephew, Namal Nawana has revamped the firm's leadership team and created strategic imperatives to put the British medical device giant on the growth track. Medtech Insight sat down with Nawana at this year's JP Morgan Healthcare Conference in San Francisco to learn more about his plans for growing Smith & Nephew.
The surgeon and serial device inventor has been getting Johnson & Johnson's Center for Device Innovation off the ground this year on the vast Texas Medical Center complex, and he says it's like nothing he has ever experienced.
Hindsight 20/20 is a Q&A feature where veterans of the medtech industry share career highlights, specific achievements and hurdles they have faced. In this installment, Kevin Brown, global VP of scientific research at radiation therapy specialist Elekta, discusses the challenges of translating scientific ideas into breakthrough technologies that bring value to clinicians and patients. He also addresses his guiding principles for picking winning ideas and his journey bringing to market the world's first integrated high-field MRI and radiotherapy system.
Medtech's biggest companies are becoming more hands-on in supporting early-stage technologies; their no longer just looking to pick up ready-to-buy assets. Among the most active in this approach is Johnson & Johnson, which has established several vehicles through which it supports and scouts external innovation. Medtech Insight chats with Mirren Mandalia, senior director of new ventures and transactions for medical devices at Johnson & Johnson Innovation, to find out what is driving J&J's technology sourcing strategy and how medtech innovators can work with the diversified health care giant.
Since selling its LifeCell aesthetic and surgical products business to Allergan in early 2017, Acelity has refocused its commercial efforts, and its name, on the KCI wound-care business, with significant investments in medical education, clinical studies and R&D in that sector, as well as the recent acquisition of UK-based Crawford Healthcare.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.